NCT02227251 2025-10-01Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics IncPhase 2 Recruiting244 enrolled 2 FDA
NCT07011056 2025-09-19A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaChengdu Zenitar Biomedical Technology Co., LtdPhase 3 Recruiting390 enrolled